IP Library Granted Patent US 11,390,909
Granted Patent B2
US 11,390,909 · App. 15/747,130 · Granted Jul 19, 2022

Nucleic acid detection method

Inventors: Henry John Lamble (Abingdon, GB); Christopher Egan (Abingdon, GB); David Lloyd (Abingdon, GB); Eryk Dunski (Abingdon, GB)
Assignee: Sense Biodetection Limited
C12Q1/682Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,390,909
App. No.
15/747,130
Granted
Jul 19, 2022
Kind
B2
Abstract

The present invention relates to methods for the detection of nucleic acids of defined sequence, and compositions and kits for use in said methods. The methods employ nicking agent(s) and a sequential series of oligonucleotide probes to produce probe fragments in the presence of a target nucleic acid.

Claims (47)

1. A method for detecting the presence of a target nucleic acid of defined sequence in a sample which method comprises the steps:

a) contacting said sample with:

i. a first oligonucleotide probe; and

ii. a nicking agent;

wherein the first oligonucleotide probe comprises a first complementarity region capable of sequence specific hybridisation to the target nucleic acid and a cleavage site for the nicking agent; and wherein the nicking agent specifically recognises double-stranded nucleic acid formed when the first oligonucleotide probe hybridises to the target nucleic acid in said sample and cleaves said first oligonucleotide probe to produce a first probe fragment;

b) contacting said first probe fragment with:

iii. a second oligonucleotide probe; and

iv. a nicking agent;

wherein the second oligonucleotide probe comprises a second complementarity region capable of sequence specific hybridisation to the first probe fragment and a cleavage site for the nicking agent; and wherein the nicking agent specifically recognises double-stranded nucleic acid formed when the second oligonucleotide probe hybridises to the first probe fragment and cleaves said second oligonucleotide probe to produce a second probe fragment;

c) optionally contacting said second probe fragment with:

v. a third oligonucleotide probe; and

vi. a nicking agent;

wherein the third oligonucleotide probe comprises a third complementarity region capable of sequence specific hybridisation to the second probe fragment and a cleavage site for the nicking agent; and wherein the nicking agent specifically recognises double-stranded nucleic acid formed when the third oligonucleotide probe hybridises to the second probe fragment and cleaves said third oligonucleotide probe to produce a third probe fragment;

d) optionally repeating step c) n times, wherein n is a positive integer, using fourth and subsequent sequential (3+n)th oligonucleotide probe(s) to produce fourth and subsequent sequential (3+n)th probe fragment(s); and

e) detecting the presence of the probe fragment produced at the end of step (b) and/or step (c) and/or step (d), wherein one or more of said detected probe fragment(s) is not capable of sequence specific hybridisation to the complementarity region of any of the preceding oligonucleotide probes to form a site that is specifically recognised and cleaved by any of the said nicking agent(s) and/or none of the probe fragments produced is capable of sequence specific hybridisation to the first complementarity region of the first oligonucleotide probe, and wherein the presence of said detected probe fragment(s) indicates the presence of the target nucleic acid in said sample.

2. A method according to claim 1 , wherein none of the probe fragments produced in steps (a), (b), and optional steps (c) and (d) are capable of sequence specific hybridisation to the complementarity region of any one of the preceding oligonucleotide probes.

3. A method according to claim 1 , wherein at least one of the oligonucleotide probes is attached to a solid material.

4. A method according to claim 1 , wherein two or more of the nicking agents in different steps (a), (b), and optional steps (c) and (d) are the same.

5. A method according to claim 1 , wherein one or more of the probe fragments produced in step (b), and optional steps (c) and (d) is attached to a moiety that permits its detection, wherein the moiety is selected from a colorimetric or fluorometric dye, and a moiety that is capable of attachment to a colorimetric dye.

6. A method according to claim 5 , wherein said moiety is an enzyme that yields a colorimetric or fluorometric signal following contact with a substrate.

7. A method according to claim 1 , wherein the presence of the probe fragment(s) in step (e) is detected by nucleic acid lateral flow.

8. A method according to claim 7 , wherein the nucleic acid lateral flow utilises one or more nucleic acid(s) capable of sequence specific hybridisation to one or more of the probe fragments in step (e).

9. A method according to claim 7 , wherein a colorimetric signal is produced with a colorimetric dye selected from the group consisting of carbon and gold.

10. A method according to claim 1 , wherein the level of target nucleic acid in said sample is quantified in step (e).

11. A method according to claim 1 , wherein one or more of the nicking agents in steps (a), (b), and optional steps (c) and (d) is selected from the group consisting of a nicking restriction endonuclease, an engineered enzyme, and a programmable nicking enzyme.

12. A method according to claim 1 , wherein one or more of the nicking agents in steps (a), (b), and optional steps (c) and (d) is a double-strand cleaving agent which functions as a nicking agent due to i) strand preference, or ii) only one of the two strands within the double-stranded nucleic acid that is specifically recognised by said double-stranded cleaving agent being capable of cleavage.

13. A method according to claim 1 , wherein one or more of the oligonucleotide probes comprises one or more modifications that render it resistant to nuclease cleavage.

14. A method according to claim 1 , wherein said target nucleic acid is selected from the group consisting of single-stranded RNA, including single-stranded RNA derived from double-stranded RNA and single-stranded RNA derived from double-stranded DNA, or single-stranded DNA, including single-stranded DNA derived from double-stranded DNA, single-stranded DNA derived from double-stranded DNA by use of a nuclease, the product of reverse transcriptase, an RNA polymerase or a DNA polymerase and a probe fragment produced following cleavage of an oligonucleotide probe by a double-strand cleaving agent.

15. A method according claim 1 , wherein the presence of two or more different target nucleic acids of defined sequence are detected in the same sample.

16. A method according to claim 15 , wherein a separate series of steps (a), (b), optional steps (c), (d), and (e) using different first, second and optionally third, fourth and subsequent sequential (3+n)th oligonucleotide probes for each of the two or more target nucleic acids is performed, which separate series of steps may be conducted simultaneously, or wherein step (a) uses a different first oligonucleotide probe for each of the two or more different target nucleic acids but the probe fragment produced in one or more of steps (a), (b), and optional steps (c) and (d) for two or more target nucleic acids is capable of hybridising to the same oligonucleotide probe in a subsequent step.

17. A method according to claim 1 , wherein said sample is selected from the group consisting of a human sample, a forensic sample, an agricultural sample, a veterinary sample, an environmental sample and a biodefence sample, including a biological sample selected from the group consisting of a nasal or nasopharyngeal swab or aspirate, blood or a sample derived from blood, and urine.

18. A method according to claim 1 , wherein said target nucleic acid is viral or derived from viral nucleic acid material, is bacterial or derived from bacterial nucleic acid material, is circulating, cell-free DNA released from cancer cells or foetal cells, or is micro RNA or derived from micro RNA.

19. A method according to claim 1 , wherein the detection of said target nucleic acid is used for the diagnosis, prognosis or monitoring of a disease or a diseased state, selected from the group consisting of an infectious disease, including but not limited to HIV, influenza, RSV, Rhinovirus, norovirus, tuberculosis, HPV, meningitis, hepatitis, MRSA, Ebola, Clostridium difficile , Epstein-Barr virus, malaria, plague, polio, Chlamydia , herpes, gonorrhoea, measles, mumps, rubella, cholera or smallpox, and a cancer, including but not limited to colorectal cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, liver cancer, bladder cancer, leukaemia, esophageal cancer, ovarian cancer, kidney cancer, stomach cancer or melanoma.

20. A method for detecting the presence of a target nucleic acid of defined sequence in a sample which method comprises the steps:

a) contacting said sample with:

i. a first oligonucleotide probe attached to a solid material; and

ii. a nicking agent;

wherein the first oligonucleotide probe comprises a first complementarity region capable of sequence specific hybridisation to the target nucleic acid and a cleavage site for the nicking agent; and wherein the nicking agent specifically recognises double-stranded nucleic acid formed when the first oligonucleotide probe hybridises to the target nucleic acid in said sample and cleaves said first oligonucleotide probe to release a first probe fragment from said solid material;

b) contacting said first probe fragment with:

iii. a second oligonucleotide probe attached to a solid material; and

iv. a nicking agent;

wherein the second oligonucleotide probe comprises a second complementarity region capable of sequence specific hybridisation to the first probe fragment and a cleavage site for the nicking agent; and wherein the nicking agent specifically recognises double-stranded nucleic acid formed when the second oligonucleotide probe hybridises to the first probe fragment and cleaves said second oligonucleotide probe to release a second probe fragment from said solid material;

c) contacting said second probe fragment with:

v. a third oligonucleotide probe attached to a solid material and attached to a colorimetric dye or a moiety capable of attachment to a colorimetric dye; and

vi. a nicking agent;

wherein the third oligonucleotide probe comprises a third complementarity region capable of sequence specific hybridisation to the second probe fragment and a cleavage site for the nicking agent; and wherein the nicking agent specifically recognises double-stranded nucleic acid formed when the third oligonucleotide probe hybridises to the second probe fragment and cleaves said third oligonucleotide probe to release a third probe fragment attached to said colorimetric dye or moiety capable of attachment to a colorimetric dye from said solid material, wherein said third probe fragments is not capable of sequence specific hybridisation to the complementarity region of any one of the preceding oligonucleotide probes to form a site that is specifically recognised and cleaved by any of the said nicking agents; and

d) detecting the presence of said third probe fragment produced at the end of step c) by colorimetric detection wherein the presence of a colorimetric signal indicates the presence of the target nucleic acid in said sample.

Assignments (8)
TERMINATION OF IP SECURITY AGREEMENT Recorded Feb 10, 2025
From: NOVALIS LIFESCIENCES INVESTMENTS II, LP
To: SHERLOCK BIOSCIENCES, INC.
Reel/Frame 070171/0448 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 68659 FRAME: 118. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Sep 24, 2024
From: SHERLOCK BIOSCIENCES, INC
To: NOVALIS LIFESCIENCES INVESTMENTS II, L.P.
Reel/Frame 069031/0946 →
SECURITY INTEREST Recorded Sep 23, 2024
From: SHERLOCK BIOSCIENCES, INC
To: NOVALIS LIFESCIENCE INVESTMENTS II, L.P.
Reel/Frame 068659/0118 →
RELEASE OF SECURITY INTEREST Recorded Jun 13, 2023
From: KDT SENSE HOLDINGS, LLC; CAMBRIDGE INNOVATION CAPITAL I LIMITED; EARLYBIRD HEALTH GMBH & CO. BETEILIGUNGS KG; MERCIA (GENERAL PARTNER) LIMITED; JONATHAN MILNER
To: SENSE BIODETECTION LIMITED
Reel/Frame 063931/0967 →
SECURITY INTEREST Recorded Jan 23, 2023
From: SENSE BIODETECTION LIMITED
To: KDT SENSE HOLDINGS, LLC; CAMBRIDGE INNOVATION CAPITAL I LIMITED; EARLYBIRD HEALTH GMBH & CO. BETEILIGUNGS KG; MERCIA (GENERAL PARTNER) LIMITED; JONATHAN MILNER
Reel/Frame 062450/0314 →
SECURITY INTEREST Recorded Dec 7, 2022
From: SENSE BIODETECTION LIMITED
To: KDT SENSE HOLDINGS, LLC
Reel/Frame 062081/0917 →
CHANGE OF ADDRESS Recorded Jun 17, 2022
From: SENSE BIODETECTION LIMITED
To: SENSE BIODETECTION LIMITED
Reel/Frame 060453/0731 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2021
From: LAMBLE, HENRY JOHN; EGAN, CHRISTOPHER; LLOYD, DAVID; DUNSKI, ERYK
To: SENSE BIODETECTION LIMITED
Reel/Frame 057128/0880 →
Priority Claims (1)
GB 1513128 · Jul 24, 2015 · national
Continuity (1)
Related Publication 20180216157A1 · Aug 2, 2018